Foley Partner Jacqueline Wright Bonilla was quoted in an article that appeared in BioWorld Insight on August 16, 2010 titled “If NIH Challenges Genzyme’s Patents, Does Anyone Care?” Wright Bonilla discusses a petition filed with the Department of Health and Human Services urging the National Institutes of Health (NIH) to exercises its march-in rights and grant an open license for the use of patents related to Genzyme Corp.’s Fabry disease drug Fabrazyme. She states that it is unlikely that the NIH would pursue an open license for Genzyme’s product because of the complexity of making biologics like Fabrazyme, adding that the agency has in fact never before exercised its march-in rights.
Related News
13 February 2025
In the News
Gregory Husisian on USMCA Viability – 'The question is in what form?'
Foley & Lardner LLP partner Gregory Husisian assessed the viability of the U.S. – Mexico – Canada Agreement (USMCA) in the IndustryWeek article, “As Tariffs Concerns Grow, Where Is the USMCA?“
13 February 2025
In the News
Nikhil Pradhan on FDA Draft AI Drug Guidance – 'The industry is very much evolving'
Foley & Lardner LLP senior counsel Nikhil Pradhan shared insight on recent draft guidance from the U.S. Food and Drug Administration's in the MedCentral article, "FDA Draft Guidance Addresses Drug Submissions that Use AI Data."
12 February 2025
In the News